QV Bioelectronics

Developing Innovative Electrotherapies for Cancer

Company Details

QV Bioelectronics are developing an implanted electrotherapy device for the treatment of glioblastoma (GBM). GBM is the most most common primary adult brain cancer, and with no cure and limited treatments available, patients are only expected to survive 14 months post-diagnosis. Our innovative electrode technology will allow us to double the life expectancy of patients by delivering electrotherapeutic currents 24/7, without impacting a patients quality of life.

The potential market size for the UK is estimated to be around £200 million/year, with the equivalent US market valued at over £1.1 billion.

Company People

Richard Fu

Richard Fu
Medical Director & Co-Founder

Qasim Akhtar

Qasim Akhtar
Business Development Officer

Chris Bullock

Chris Bullock
CEO & Co-Founder

You might also be interested in

No Offer, Solicitation, Advice, or Recommendation

Except to the extent expressly set forth in materials as may be provided through a password protected area on the SOSV website (the "Materials"), or as otherwise expressly specified by SOSV in writing, nothing on the SOSV website is intended to constitute (i) an offer, or solicitation of an offer, to purchase or sell any security, other asset or service, (ii) investment advice or an offer to provide such advice, or (iii) a basis for making any investment decision.  Except as expressly stated by SOSV in writing, neither the SOSV website nor any of the Materials make any effort to present a comprehensive or balanced description of SOSV or its investment activities.